- Home
- ALXO vs INVE Comparison
ALXO vs INVE Comparison
Compare ALXO & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | INVE |
|---|---|---|
| Founded | 2015 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.7M | 80.1M |
| IPO Year | 2020 | 1997 |
Fundamental Metrics
Financial Performance| Metric | ALXO | INVE |
|---|---|---|
| Price | $1.33 | $3.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $3.30 | ★ $5.50 |
| AVG Volume (30 Days) | ★ 177.3K | 40.3K |
| Earning Date | 11-07-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $22,015,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.82 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.40 | $2.86 |
| 52 Week High | $2.27 | $4.07 |
Technical Indicators
Market Signals| Indicator | ALXO | INVE |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 45.52 |
| Support Level | $1.37 | $3.40 |
| Resistance Level | $1.53 | $3.70 |
| Average True Range (ATR) | 0.11 | 0.15 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 12.12 | 23.84 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.